The Effect of Bevacizumab on Corneal Neovascularization (BQ-1-08-ARVO)

Instituto de Olhos de Goiania

Status and phase: Completed; Phase 4

Conditions: Corneal Neovascularization

Treatments: Drug: Bevacizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT00797303

BQ-1-08-ARVO

Details and patient eligibility

About

Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.

Full description

To evaluate the effect of repeated subconjunctival bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) on inflammatory corneal neovascularization.

Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.

Enrollment: 8 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Corneal Neovascularization
• Stable lesion

Exclusion criteria

• Diabetes
• Autoimmune diseases

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: Single Blind

---

8 participants in 1 patient group

1

Experimental group

Description:

A single intraoperative subconjunctival application of bevacizumab and 2 months follow-up

Treatment:

Drug: Bevacizumab